Cholangitis (primary sclerosing, PSC), with reimbursement 202

K11_CHOLANGI_STRICT

sclerosing cholangitis: A chronic, autoimmune inflammatory liver disorder characterized by narrowing and scarring of the lumen of the bile ducts. It is often seen in patients with ulcerative colitis. Signs and symptoms include jaundice, fatigue, and malabsorption. It may lead to cirrhosis and liver failure.

Endpoint definition

↥

FinnGen phenotype data

321302 individuals

Apply sex-specific rule None

321302

Check conditions

K11_REIMB_202

16690

Filter registries

Hospital Discharge: ICD-10 K83.0

Hospital discharge: ICD-9 5761

Hospital discharge: ICD-8 5750[4-5]

Cause of death: ICD-10 K83.0

Cause of death: ICD-9 5761

Cause of death: ICD-8 5750[4-5]

386

Check pre-conditions, main-only, mode, ICD version

Look only at ICD versions H.D: 10, 8, 9 ; C.O.D: 10, 8, 9

386

Check minimum number of events None

386

Include endpoints None

386

K11_CHOLANGI_STRICT

Extra metadata

First used in FinnGen datafreeze DF3

Parent code in ICD-10 K83

Name in latin Cholangitis

Similar endpoints

↥

List of similar endpoints to Cholangitis (primary sclerosing, PSC), with reimbursement 202 based on the number of shared cases.

Broader endpoints:

Narrower endpoints:

Show all endpoint correlations

Summary Statistics

↥

Key figures

	All	Female	Male
Number of individuals	376	209	167
Unadjusted prevalence (%)	0.12	0.12	0.12
Mean age at first event (years)	42.67	45.65	38.93

Mortality

Follow-up	Absolute risk	HR [95% CI]	p	N
1998–2019	0.02	1.30 [0.43, 3.97]	6.4e-1	16
15 years	-	-	-	-
5 years	-	-	-	-
1 year	-	-	-	-

Age distribution of first events

Year distribution of first events

Cumulative Incidence

Correlations

↥

Index endpoint: K11_CHOLANGI_STRICT – Cholangitis (primary sclerosing, PSC), with reimbursement 202
GWS hits: 1

Survival analyses between endpoints

↥

Plot

before Cholangitis (primary sclerosing, PSC), with reimbursement 202
after Cholangitis (primary sclerosing, PSC), with reimbursement 202

Loading survival analyses plot

Table

Loading survival analyses table

Drugs most likely to be purchased after Cholangitis (primary sclerosing, PSC), with reimbursement 202

↥